natgillin/translations-raw huggingface dataset:
Kui kaitseväide esitatakse pärast artikli 6 lõikes 3 sätestatud tähtaja aegumist, kuid artikli 9 lõikes 3 täpsustatud tähtaja jooksul, omab see sama toimet kui vastulause esitamine.
A statement of defence lodged after the expiry of the time limit laid down in Article 6 (3) but within the time limit specified in Article 9 (3) shall produce the same effects as entering a statement of opposition.
Kõiki menetlusküsimusi, mida ei ole konkreetselt käesolevas määruses käsitletud, reguleeritakse selle liikmesriigi õigusaktidega, milles Euroopa maksumenetluse kord aset leiab.
All procedural issues not specifically dealt with in this Regulation shall be governed by the law of the Member State in which the European order for payment proceedings take place.
Seda sätet kasutades ei tohi liikmesriigid siiski püüda kehtestada lisamenetluse või tõenditega seotud tingimusi, millel oleks Euroopa maksekorraldust kahjustav mõju.
However, in taking advantage of this provision Member States shall not seek to introduce further procedural or evidential requirements which would have the effect of undermining the European order for payment.
Seeks to ensure effective operation of the European Payment Order procedure.
Seeks to ensure effective operation of the European Payment Order procedure.
Viis aastat pärast käesoleva määruse jõustumist esitab komisjon Euroopa Parlamendile ja nõukogule teatise, mis käsitleb Euroopa maksumenetluse korra kohaldamist.
Five years after the entry into force of this Regulation, the Commission shall present to the European Parliament and the Council a detailed report on the operation of the European order for payment procedure.
Teatis peab sisaldama menetluse toimimise majandusanalüüsi ja laiendatud mõju-uuringut iga liikmesriigi kohta, sealhulgas menetluse võimaliku riiklikele juhtumitele laiendamise tasuvusanalüüsi.
That report shall contain an economic assessment of the procedure as it has operated and an extended impact assessment for each Member State , including a cost-benefit analysis of the possible extension to purely national cases.
Kui teatisest selgub, et menetlus on lihtne, mõjus ja tasuv ning võimaldab tõhusat õiguskaitset, võib komisjon esitada Euroopa Parlamendile ja nõukogule ettepaneku meetme rakendamiseks, et lihtsustada Euroopa maksekorralduse menetluse kasutamist liikmesriikides riiklike juhtumite korral ja teha sellekohaseid ettepanekuid käesolevasse määrusesse, võttes eriliselt arvesse menetluse piirüleste juhtumitega omandatud kogemusi ja nende liikmesriikide kogemusi, kes kasutavad menetlust riiklike juhtumite korral.
In the event that the report can demonstrate that the procedure is simple, efficient and cost-effective, and that it offers effective redress, the Commission may present a proposal to the European Parliament and the Council for a measure facilitating the use of the European order for payment procedure in Member States for national cases and proposing such amendments to this Regulation as are necessary to that end having regard in particular to the experience gained in using the procedure for cross-border cases and those Member States using the procedure for national cases.
kodanikuvabaduste, justiits- ja siseasjade komisjonI ARVAMUS
OPINION of the Committee on Civil Liberties, Justice and Home Affairs
Ettepanek võtta vastu Euroopa Parlamendi ja nõukogu määrus, millega luuakse Euroopa maksumenetluse kord
on the proposal for a European Parliament and Council regulation creating a European order for payment procedure
(8) The European order for payment procedure should not replace or harmonise the existing mechanisms for the recovery of uncontested debts under national law but constitute an additional option for the creditor who remains free to resort to a procedure provided by domestic law .
(8) The European order for payment procedure should not replace or harmonise the existing mechanisms for the recovery of uncontested debts under national law but constitute an additional option for the creditor who remains free to resort to a procedure provided by domestic law .
(8) The European order for payment procedure loob piiriülese kaubanduse toetamise eesmärgil füüsilistele ja juriidilistele isikutele kogu Euroopa Liidus kindla õigusliku raami, nähes ette lihtsustatud menetluse piiriüleste vaidluste korral.
(8) The European order for payment procedure will create for natural and legal persons throughout the EU a secure legal framework providing a simplified procedure in cross-border cases to assist cross-border business.
Samuti peaks see olema eeskujuks siseriiklikele õigussüsteemidele, eelkõige juhtudel, kus samalaadne tõhus menetlus seni puudub.
In this way, the European order for payment procedure should also serve as a model for national legal systems, in particular where such efficient procedures do not yet exist .
(10) The procedure should be based, to the largest extent possible, on the use of standard forms in the communication between the court and the parties in order to facilitate its administration and enable the use of automatic data processing.
(10) The procedure should be based, to the largest extent possible, on the use of standard forms in the communication between the court and the parties in order to facilitate its administration and enable the use of automatic data processing.
(10) The procedure should be based, to the largest extent possible, on the use of standard forms in the communication between the court and the parties in order to facilitate its administration, ning liikmesriik peaks ergutama the use of automatic data processing.
(10) The procedure should be based, to the largest extent possible, on the use of standard forms in the communication between the court and the parties in order to facilitate its administration, and the Member States should encourage the use of automatic data processing.
This Regulation shall apply in civil and commercial matters, whatever the nature of the court or tribunal.
This Regulation shall apply in civil and commercial matters, whatever the nature of the court or tribunal.
It shall not extend, in particular, to revenue, customs or administrative matters.
It shall not extend, in particular, to revenue, customs or administrative matters.
This Regulation shall apply piiriüleste vaidluste suhtes in civil and commercial matters, whatever the nature of the court or tribunal.
This Regulation shall apply in cross-border cases to civil and commercial matters, whatever the nature of the court or tribunal.
(e) the brief description of at least one means of evidence that could be adduced in ordinary civil proceedings to support the claim.
(e) the brief description of at least one means of evidence that could be adduced in ordinary civil proceedings to support the claim.
Viis aastat pärast käesoleva määruse jõustumist esitab komisjon Euroopa Parlamendile ja nõukogule aruande.
Five years after the entry into force of this Regulation, the Commission shall present a report to the European Parliament and the Council..
Ettepanek võtta vastu Euroopa Parlamendi ja nõukogu määrus, millega luuakse Euroopa maksumenetluse kord
Proposal for a European Parliament and Council regulation creating a European order for payment procedure
Ettepanek võtta vastu Euroopa Parlamendi ja nõukogu määrus, millega luuakse Euroopa maksumenetluse kord
Proposal for a regulation of the European Parliament and of the Council creating a European order for payment procedure
art 251 lg 2 ja art 61 punkt c (EÜ)
Articles 251(2) and 61 (c) EC
Evelin Lichtenberger, Arlene McCarthy, Toine Manders, Edith Mastenbroek, Manuel Medina Ortega, Ingo Schmitt, József Szájer
Evelin Lichtenberger, Arlene McCarthy, Toine Manders, Edith Mastenbroek, Manuel Medina Ortega, Ingo Schmitt, József Szájer
Ettepanek võtta vastu nõukogu otsus Euroopa Majandusühenduse ja Türgi vahelise assotsieerumislepingu lisaprotokolli sõlmimise kohta seoses Euroopa Liidu laienemisega
on the proposal for a Council decision on the conclusion of the Additional Protocol to the Agreement establishing an Association between the European Economic Community and Turkey following the enlargement of the European Union
PE 360.099v01-00
PE 360.099v01-00
– võttes arvesse ettepanekut võtta vastu nõukogu otsus ( KOM(2005)0191 )
– having regard to the proposal for a Council decision ( COM(2005)0191 )
– võttes arvesse nõukogu teksti (9617/2005);
- having regard to the text of the Council (9617/2005),
– võttes arvesse nõukogu esitatud nõusoleku taotlust vastavalt EÜ asutamislepingu artikli 300 lõike 3 teisele lausele koostoimes artikli 300 lõike 2 esimese lõigu teise lausega ja artikliga 310 ( C6-0194/2005 );
– having regard to the request for assent submitted by the Council pursuant to Article 300(3), second subparagraph, in conjunction with Article 300(2), first subparagraph, second sentence and Article 310 of the EC Treaty ( C6‑0194/2005 ),
– võttes arvesse kodukorra artiklit 75, artikli 83 lõiget 7 ning artikli 43 lõiget 1;
– having regard to Rules 75, 83(7) and 43(1) of its Rules of Procedure,
– võttes arvesse väliskomisjoni soovitust ( A6‑0241/2005 ),
– having regard to the recommendation of the Committee on Foreign Affairs ( A6‑0241/2005 ),
Ettepanek võtta vastu nõukogu otsus Euroopa Majandusühenduse ja Türgi vahelise assotsieerumislepingu lisaprotokolli sõlmimise kohta seoses Euroopa Liidu laienemisega
Proposal for a Council decision on the conclusion of the Additional Protocol to the Agreement establishing an Association between the European Economic Community and Turkey following the enlargement of the European Union
art 300 lg 3 teine lõik, art 300 lg 2 esimese lõigu teine lause ja art 310 (EÜ)
Article 300(3), second subparagraph, 300(2), first subparagraph, second sentence and 310 EC
art 43 lg 12 1.6.2005
Rule 43(1) 21.6.2005
Ettepanek võtta vastu Euroopa Parlamendi ja nõukogu määrus, milles käsitletakse tervishoiuprobleemidega riikidesse eksportimiseks toodetavate farmaatsiatoodete patentide sundlitsentsimist
on the proposal for a regulation of the European Parliament and of the Council on compulsory licensing of patents relating to the manufacture of pharmaceutical products for export to countries with public health problems
EXPLANATORY STATEMENT..............................................................................................32
EXPLANATORY STATEMENT..............................................................................................33
ARENGUKOMISJONI ARVAMUS........................................................................................36
OPINION of the Committee on Development ......................................................37
KESKKONNA-, RAHVATERVISE- JA TOIDUOHUTUSE KOMISJONI ARVAMUS........50
OPINION of the Committee on the Environment, Public Health and Food Safety 52
ÕIGUSKOMISJONI ARVAMUS............................................................................................72
OPINION of the Committee on Legal Affairs ......................................................75
– võttes arvesse komisjoni ettepanekut Euroopa Parlamendile ja nõukogule ( KOM(2004)0737 )
– having regard to the Commission proposal to the European Parliament and the Council ( COM(2004)0737 )
– võttes arvesse EÜ asutamislepingu artikli 251 lõiget 2 ja artikleid 95 ning 133, mille alusel komisjon Euroopa Parlamendile ettepaneku esitas ( C6‑0168/2004 );
– having regard to Article 251(2) and Articles 95 and 133 of the EC Treaty, pursuant to which the Commission submitted the proposal to Parliament ( C6‑0168/2004 ),
– võttes arvesse rahvusvahelise kaubanduse komisjoni raportit ning arengukomisjoni, keskkonna-, rahvatervise- ja toiduohutuse komisjoni ja õiguskomisjon arvamusi ( A6‑0242/2005 ),
– having regard to the report of the Committee on International Trade and the opinions of the Committee on Development, the Committee on the Environment, Public Health and Food Safety and the Committee on Legal Affairs ( A6‑0242/2005 ),
(6) Kuna käesoleva määruse alusel sätestatud sundlitsentsimissüsteem on ette nähtud tervisekaitseprobleemide lahendamiseks, tuleb seda kasutada heauskselt.
(6) As the compulsory licensing system set up by this Regulation is intended to address public health problems, it should be used in good faith.
Seda ei tohi kasutada esmajärjekorras muude eesmärkide saavutamiseks ega ainult kaubanduslikul eesmärgil.
It should not be used with the primary purpose of addressing other objectives, and in particular objectives of a purely commercial nature .
Käesoleva määrusega püütakse ära hoida kohtuvaidlusi kehtestatud süsteemi suhtes.
This Regulation aims to discourage litigation with regard to the established system .
(6 a) Maailma tasemel suudab tervishoiualane teadus- ja arendustegevus vastata vaeste maade tervishoiuvajadustele üksnes osaliselt.
(6a) Research and development in the field of health at a global level only partially answers health needs in poor countries.
Et selle olukorraga toime tulla, peab nii ruttu kui võimalik võtma meetmeid nende maade tehnilise suutlikkuse parandamiseks.
In order to address this situation, measures should be implemented as soon as possible, with a view to improving the technical capacity of those countries.
The desirability of the transfer of technology to developing and least‑developed countries is set out in the Decision of 30 August, but not incorporated in the regulation.
The desirability of the transfer of technology to developing and least‑developed countries is set out in the Decision of 30 August, but not incorporated in the regulation.
(7) Käesoleva määruse alusel valmistatud tooted peavad jõudma vajajateni ning neid ei tohi kõrvale suunata neist, kellele need olid ette nähtud.
(7) Products manufactured pursuant to this Regulation should reach those who need them and should not be diverted from those for whom they were intended.
Käesoleva määruse alusel väljastatud sundlitsentsidega tuleb seega kehtestada selged tingimused litsentsisaajale, mis käsitleb tegevusi, mille suhtes litsents kehtib, litsentsi alusel toodetud farmaatsiatoodete identifitseerimist ning riike, kuhu need tooted imporditakse.
Compulsory licences issued under this Regulation should therefore impose clear conditions upon the licensee as regards the acts covered by the licence, the identification of the pharmaceutical products manufactured under the licence and the countries to which these products will be exported.
(7) Käesoleva määruse alusel valmistatud tooted peavad jõudma ainult nendeni, kes neid vajavad, ning neid ei tohi kõrvale suunata neist, kellele need olid ette nähtud.
(7) Products manufactured pursuant to this Regulation must reach only those who need them and should not be diverted from those for whom they were intended.
Sundlitsentside väljastamine käesoleva määruse alusel peab seega kehtestama litsentsisaajale selged tingimused, mis puudutavad litsentsiga hõlmatud tegevusi, litsentsi alusel toodetud farmaatsiatoodete identifitseerimist ning riike, kuhu need tooted imporditakse.
The issuing of compulsory licences under this Regulation must therefore impose clear conditions upon the licensee as regards the acts covered by the licence, the identification of the pharmaceutical products manufactured under the licence and the countries to which these products will be exported.
(9) Et vältida ületootmise hõlbustamist ja võimalikku toodete levitamist, peaksid pädevad asutused arvestama samade toodete ja riikide olemasolevaid sundlitsentse ning taotleja poolt samaaegselt esitatud taotlusi.
(9) To avoid facilitating overproduction and possible diversion of products, competent authorities should take into account existing compulsory licences for the same products and countries, as well as parallel applications indicated by the applicant.
Kus neid veel pole, tuleb luua selleks vajalikud andmevahetusvõrgud.
Where they do not already exist, the data exchange networks necessary for this purpose should be created.
(10 a) Ühendus tunnistab, et käesolevas määruses ette nähtud meetmed ei ole piisavad küllaldase juurdepääsu tagamiseks geneerilistele ravimitele arengumaades ja et kiiremas korras tuleb võtta lisameetmeid, mille eesmärgiks on:
(10a) The Community recognises that the measures provided for in this Regulation are not sufficient to guarantee adequate access to generic medicines in developing countries and that it must take additional measures as a matter of urgency with a view to:
– ravimite tootmise ja uuringute ergutamine Euroopa Liidus, et võidelda arengumaid tabavate suurte epideemiatega; ning
- encouraging within the European Union the production of medicines and research to combat the major epidemics affecting developing countries; and
– tehnosiirde, teadusuuringute, võimekuse suurendamise, piirkondlike tarnesüsteemide ja abi ergutamine registreerimisel, eesmärgiga hõlbustada ja suurendada farmaatsiatoodete tootmist arengumaade endi poolt.
- encouraging the transfer of technology, research, capacity strengthening, regional supply systems and help with registration, in order to facilitate and increase the production of pharmaceutical products by the developing countries themselves.
Käesoleva määrusega kehtestatakse sundlitsentside andmise tingimused, mis käsitlevad patente ja täiendava kaitse tunnistusi farmaatsiatoodete valmistamiseks ja müügiks, kui niisugused tooted on mõeldud ekspordiks abikõlblikesse tervishoiuprobleemidega WTO liikmesriikidesse .
This Regulation establishes a procedure for the grant of compulsory licences in relation to patents and supplementary protection certificates concerning the manufacture and sale of pharmaceutical products, when such products are intended for export to eligible WTO members affected by public health problems .
Liikmesriigid annavad sundlitsentsi igale inimesele, kes esitab taotluse kooskõlas artikliga 5 ja vastavalt artiklites 5–8 sätestatud tingimustele.
Member States shall grant a compulsory licence to any person making an application in accordance with Article 5 and subject to the conditions set out in Articles 5 – 8.
Käesoleva määrusega kehtestatakse sundlitsentside andmise tingimused, mis käsitlevad patente ja täiendava kaitse tunnistusi farmaatsiatoodete valmistamiseks ja müügiks, kui niisugused tooted on mõeldud ekspordiks abikõlblikesse importivatesse riikidesse .
This Regulation establishes a procedure for the grant of compulsory licences in relation to patents and supplementary protection certificates concerning the manufacture and sale of pharmaceutical products, when such products are intended for export to eligible importing countries .
Artikli 2 lõige 3
Article 2, paragraph (3)
3) importiv WTO liige – WTO liikme nimi, kuhu farmaatsiatoodet eksporditakse;
(3) “importing WTO member ” means the name of the WTO member to which the pharmaceutical product is to be exported;
3) importiv riik – WTO liikme , arengumaa või vähimarenenud maa nimi, kuhu farmaatsiatoodet eksporditakse;
(3) “importing country ” means the name of the WTO member , of the developing country or of the least-developed country to which the pharmaceutical product is to be exported;
Abikõlblikud importivad riigid on järgmised:
The following are eligible importing countries :
a) kõik vähimarenenud riigid , kes on WTO liikmed
(a) any least-developed country member of WTO
a) kõik vähimarenenud riigid ;
(a) any least-developed country
b) iga muu WTO liige, kes on teavitanud TRIPSi nõukogu oma soovist süsteemi kasutada importijana, lisades, kas süsteemi kasutatakse täies või piiratud ulatuses.
(b) any other member of WTO that has made a notification to the Council for TRIPs of its intention to use the system as an importer, including whether it will use the system in whole or in a limited way.
b) iga muu WTO liige, kes on teavitanud TRIPSi nõukogu oma soovist süsteemi kasutada importijana, lisades, kas süsteemi kasutatakse täies või piiratud ulatuses ;
(b) any other member of WTO that has made a notification to the Council for TRIPs of its intention to use the system as an importer, including whether it will use the system in whole or in a limited way.
c) iga arengumaa, kes pole WTO liige ja on teavitanud komisjoni oma soovist süsteemi kasutada importijana, lisades, kas süsteemi kasutatakse täies või piiratud ulatuses.
(c) any developing country that is not a member of WTO and has made a notification to the Commission of its intention to use the system as an importer, including whether it will use the system in whole or in a limited way.
Iga WTO liige, kes on esitanud WTOle avalduse, et ta ei kasuta süsteemi kui importiv WTO liige, ei ole siiski abikõlblik importiv WTO liige .
However, any WTO member that has made a declaration to the WTO that it will not use the system as an importing WTO member is not an eligible importing WTO member .
Iga WTO liige, kes on esitanud WTOle avalduse, et ta ei kasuta süsteemi kui importiv WTO liige, ei ole siiski abikõlblik importiv riik .
However, any WTO member that has made a declaration to the WTO that it will not use the system as an importing WTO member is not an eligible importing country .
Kui sundlitsentsi taotlev isik esitab taotlused pädevatele asutustele sama toote kohta rohkem kui ühes liikmesriigis, peab ta taotluses selle ära märkima koos koguste ja asjassepuutuvate importivate WTO liikmetega .
If the person applying for a compulsory licence is submitting applications to competent authorities in more than one Member State for the same product, he shall indicate that in each application, together with details of the quantities and importing WTO members concerned.
Kui sundlitsentsi taotlev isik esitab taotlused pädevatele asutustele sama toote kohta rohkem kui ühes liikmesriigis, peab ta taotluses selle ära märkima koos koguste ja asjassepuutuvate importivate riikidega .
If the person applying for a compulsory licence is submitting applications to competent authorities in more than one Member State for the same product, he shall indicate that in each application, together with details of the quantities and importing countries concerned.
Artikli 5 lõike 3 punkt a
Article 5, paragraph 3, point (a)
a) taotleja ja taotleja poolt määratud agendi või esindaja nimi ja kontaktandmed, kes tema eest pädeva asutuse ees tegutseb;
(a) the name and contact details of the applicant and of any agent or representative the applicant has appointed to act for him before the competent authority;
a) taotleja ja õiguse valdaja ning taotleja poolt määratud agendi või esindaja nimi ja kontaktandmed, kes tema eest pädeva asutuse ees tegutseb;
(a) the name and contact details of the applicant and rights holder and of any agent or representative the applicant has appointed to act for him before the competent authority;
Artikli 5 lõike 3 punkt b
Article 5, paragraph 3, point (b)
b) farmaatsiatoote nimi või toodete nimed, mida taotleja soovib sundlitsentsi alusel ekspordiks toota ja müüa , sh vajalik lisateave, et tagada vastava toote või toodete täpne identifitseerimine ;
(b) the name of the pharmaceutical product or products the applicant intends to manufacture and sell for export under the compulsory licence, including any additional information needed to ensure the precise identification of the product or products in question;
b) farmaatsiatoote nimi või toodete nimed, mida taotleja soovib sundlitsentsi alusel ekspordiks toota ja müüa;
(b) the name of the pharmaceutical product or products the applicant intends to manufacture and sell for export under the compulsory licence,
Artikli 5 lõike 3 punkt c
Article 5, paragraph 3, point (c)
c) patendi (patentide) ja/või täiendava kaitse tunnistus(t)e tähis, mille jaoks sundlitsentsi taotletakse;
(c) identification of the patent(s) and/or supplementary protection certificate(s) in respect of which a compulsory licence is sought;
Artikli 5 lõike 3 punkt d
Article 5, paragraph 3, point (d)
d) farmaatsiatoote kogus, mida taotleja soovib toota sundlitsentsi alusel;
(d) the amount of pharmaceutical product which the applicant seeks to produce under the compulsory licence;
d) farmaatsiatoote kogus, mida taotleja soovib toota sundlitsentsi alusel vastavalt artikli 8 lõikele 2 ;
(d) the amount of pharmaceutical product which the applicant seeks to produce under the compulsory licence , in accordance with Article 8(2) ;
Artikli 5 lõike 3 punkt e
Article 5, paragraph 3, point (e)
e) importiv WTO liige või liikmed ;
(e) the importing WTO member or members ;